多西他赛联合顺铂治疗47例进展期非小细胞肺癌的疗效观察

目的:观察多西他赛联合顺铂治疗进展期非小细胞肺癌疗效及不良反应。方法:47例患者给予多西他赛75 mg/m2加入5%葡萄糖注射液500 mL,静脉滴注2 h,第1天;顺铂1次30 mg/m2,连用3 d,21 d为1个周期,2个周期以上评价疗效。结果:47例可评价疗效的患者中,完全缓解(CR)2例,部分缓解(PR)19例,总有效率为44.68%(21/47);中位生存期(MST)11.0个月,1年生存率为42.55%(20/47);主要不良反应为骨髓抑制。结论:多西他赛联合顺铂是治疗进展期非小细胞肺癌的有效化疗方案。

Effect of docetaxel with cisplatin in treating advanced non-small cell lung cancer

Objective：To evaluate the effect and toxicity of docetaxel with cisplatin in treating patients with advanced non-small cell lung cancer（NSCIC）.Methods：Forty-seven patients received chemotherapy with docetaxel with cisplatin as follows：docetaxel（75 mg/m2）iv on day1,and cisplatin（30 mg/m2） iv day 2 to day 4.One therapy course contained 21 days and clinical efficacy was evaluated after 2 courses.Results：The total effective rates（（CR＋PR） were 44.68%（21/47）.The median survival time（MST） was 11.0 months.The 1-year survival was 42.5%（20/47）.The major adverse reaction was arrestofbonemarrow.Conclusions：The combination of docetaxel and cisplatin is a feasible,well-tolerated and effective treatment for Advanced NSCLC patients.